Premenopausal women with HR-positive, HER2-negative, lymph node-positive breast cancer and a risk for recurrence experienced benefits with chemotherapy plus endocrine therapy, with improvements in five-year invasive disease-free and overall survival.
In this phase 3 trial, Verzenio with endocrine therapy reduced the risk for invasive disease recurrence and death versus endocrine therapy alone for patients with high-risk, early hormone receptor–positive, HER2-negative breast cancer.
Prior to receiving behavioral interventions, more than half of participating young survivors of breast cancer were considered clinically depressed. That number dropped to 30% after participants received mindfulness meditation and survivorship education classes.
Women with higher diet adherence scores after diagnosis had a 33% lower risk for all-cause mortality and a 17% lower risk for mortality related to breast cancer compared with women with lower diet adherence scores.
Of note, the results indicated that patients with breast cancer who were younger than 60 and of Black or other race were more likely to experience under-recognized symptoms by their physician.
Younger age, breast cancer diagnosis, Medicaid insurance and treatment type were associated with an increased risk for women becoming new chronic users of opioids or sedatives/hypnotics following mastectomy with reconstructive surgery.
